C5 and age-related macular degeneration: A crucial complement component, C5, has become a primary therapeutic target for many inflammatory diseases, including AMD.182 As a C5 inhibitor, avacincaptad pegol has been shown to slow GA progression by targeting the source of retinal cell death.